Format

Send to

Choose Destination
Arch Esp Urol. 2010 Oct;63(8):740-7.

The future of erectile dysfunction (ED).

[Article in English, Spanish]

Author information

1
European Society for Sexual Medicine Standards Committee for Sexual Medicine of the International Society for Sexual Medicine, Hamburg, Germany. 20354@aol.com

Abstract

About 30-40 % of ED patients are non-responders to PDE 5 inhibitor monotherapy. Lifestyle modifications and physical activity with weight loss enhance PDE 5 inhibitor responsiveness. The same applies for combination therapies such PDE 5 inhibitors + L-Arginine 3.000mg, PDE 5 inhibitors + statins and PDE 5 inhibitors + Yohimbine. Combination of daily dosing with Tadalafil 5 mg and on demand application of sildenafil or vardenafil can improve responsiveness and erection hardness (personal experiences). Guanylate cyclase activators or RhoA-kinase inhibitors, either as monotherapy or in combination with PDE 5 inhibitors have shown in preclinical settings the potential to improve erectile function and represent targets for new ED drugs in the future. Immunophilin ligands were able to ameliorate erectile function after cavernous nerve injury due to pelvic surgery. Although having shown convincing efficacy both in animals and humans the centrally acting Melanocortin Receptor (MCR) Agonists were given up for ED treatment because of unfavorable side-effects.Promising targets for ED therapy in the future is gene therapy with several targets as well as stem cell therapy with adipose-derived or muscle-derived stem cells.

PMID:
21048284
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Archivos Espanoles de Urologia
Loading ...
Support Center